The advanced imaging-guided approach to acute ischemic stroke in the extended reperfusion time window

Abstract

Evaluation and treatment of acute ischemic stroke has undergone significant advancement since the 1990s, when acute systemic reperfusion with intravenous alteplase became the first approved method for achieving reperfusion. Until recently, 4.5 h after stroke onset appeared to be the maximum time window in which positive results from thrombolysis can be achieved. However, the advent of advanced imaging modalities, including multimodal magnetic resonance imaging and computed tomography perfusion has allowed clinicians to refine the evaluation of these patients by delineating areas of infarcted tissue, areas of potentially salvageable tissue given timely reperfusion, and areas of benign oligemia. Early work in extending the time window beyond this historical limit of 4.5 h has culminated in four positive trials that demonstrate the benefit of acute mechanical or systemic reperfusion therapy in an extended time window of up to 24 h, using advanced imaging criteria for patient selection. The implications of the success of advanced imaging suggest use of these modalities for disposition decisions and selection of greater numbers of patients for reperfusion but add complexity to individual patient evaluation. Despite this, many questions remain unanswered, including the best choice of thrombolysis agent, whether we can extend the time window further to 24 h, and the optimal combination of mechanical thrombectomy and bridging therapy in the late time window in patients with or without large vessel occlusion.

Keywords

Stroke / reperfusion / thrombectomy / tissue plasminogen activator / fibrinolytic agents / computed tomography / magnetic resonance imaging

References

[1] Albers GW,Kemp S.Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.New Engl J Med2018;378:708-18 PMCID:PMC6590673

[2] Nogueira RG,Haussen DC.Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct.New Engl J Med2018;378:11-21

[3] Ma H,Parsons MW.Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke.N Engl J Med2019;380:1795-803

[4] Thomalla G,Boutitie F.WAKE-UP InvestigatorsMRI-guided thrombolysis for stroke with unknown time of onset.N Engl J Med2018;379:611-22

[5] Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.New Engl J Med1995;333:1581-7

[6] Hacke W,Bluhmki E.Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.New Engl J Med2008;359:1317-29

[7] Emberson J,Lyden P.Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.Lancet2014;384:1929-35 PMCID:PMC4441266

[8] Lees KR,Blackwell L.Effects of alteplase for acute stroke on the distribution of functional outcomes.Stroke2016;47:2373-9 PMCID:PMC5024752

[9] Astrup J,Branston NM.Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia.Stroke1977;8:51-7

[10] Astrup J,Symon L.Thresholds in cerebral ischemia - the ischemic penumbra.Stroke1981;12:723-5

[11] Thirugnanachandran T,Singhal S.Refining the ischemic penumbra with topography.Int J Stroke2018;13:277-84

[12] Davis S.Time is penumbra: imaging, selection and outcome.Cerebrovasc Dis2014;38:59-72

[13] Markus R,Kazui S.Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival.Brain2004;127:1427-36

[14] Kidwell CS,Saver JL.Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging.Stroke2003;34:2729-35

[15] Purushotham A,Straka M.Apparent diffusion coefficient threshold for delineation of ischemic core.Int J Stroke2015;10:348-53 PMCID:PMC3786020

[16] Olivot JM,Thijs VN.Optimal Tmax threshold for predicting penumbral tissue in acute stroke.Stroke2009;40:469-75 PMCID:PMC2670783

[17] Ma HK,Churilov L.The hidden mismatch: an explanation for infarct growth without perfusion-weighted imaging/diffusion-weighted imaging mismatch in patients with acute ischemic stroke.Stroke2011;42:662-8

[18] Ma H,Teoh H.Penumbral mismatch is underestimated using standard volumetric methods and this is exacerbated with time.J Neurol Neurosurg Psychiatry2009;80:991-6

[19] Campbell BC,Levi CR.Comparison of computed tomography perfusion and magnetic resonance imaging perfusion-diffusion mismatch in ischemic stroke.Stroke2012;43:2648-53

[20] Wintermark M,Cuisenaire O.Comparison of admission perfusion computed tomography and qualitative diffusion-and perfusion-weighted magnetic resonance imaging in acute stroke patients.Stroke2002;33:2025-31

[21] Davis SM,Parsons MW.Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.Lancet Neurol2008;7:299-309

[22] Albers GW,Wechsler L.DEFUSE InvestigatorsMagnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.Ann Neurol2006;60:508-17

[23] Picanço MR,Campbell BC.Reperfusion after 4.5 hours reduces infarct growth and improves clinical outcomes.Int J Stroke2014;9:266-9

[24] Ogata T,Nagakane Y.The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset.Stroke2013;44:87-93

[25] Albers GW,Truelsen T.Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet Neurol2015;14:575-84

[26] Campbell BC,Foster SJ.EPITHET InvestigatorsVisual assessment of perfusion-diffusion mismatch is inadequate to select patients for thrombolysis.Cerebrovasc Dis2010;29:592-6

[27] Campbell BC.Imaging selection for acute stroke intervention.Int J Stroke2018;13:554-67

[28] Campbell BC,Ma H.Imaging selection in ischemic stroke: feasibility of automated CT-perfusion analysis.Int J Stroke2015;10:51-4

[29] Ma H,Christensen S.A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).Int J Stroke2012;7:74-80

[30] Thomalla G,Østergaard L.A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP).Int J Stroke2014;9:829-36

[31] Thomalla G.Acute imaging for evidence-based treatment of ischemic stroke.Curr Opin Neurol2019;32:521-9

[32] Koga M,Inoue M.THAWS Trial InvestigatorsThrombolysis with alteplase at 0.6 mg/kg for stroke with unknown time of onset.Stroke2020;51:1530-8 PMCID:PMC7185058

[33] Ringleb P,Bluhmki E.Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection.Int J Stroke2019;14:483-90

[34] Schwamm LH,Song SS.Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results.Ann Neurol2018;83:980-93 PMCID:PMC6095471

[35] Campbell BC,Ringleb PA.EXTENDECASS-4and EPITHET InvestigatorsExtending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.Lancet2019;394:139-47

[36] Tsivgoulis G,Malhotra K.Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window.Neurology2020;94:e1241

[37] Thomalla G,Ma H.Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigatorsIntravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.Lancet2020;396:1574-84 PMCID:PMC7734592

[38] Stroke Foundation. Clinical Guidelines for Stroke Management.

[39] Powers WJ,Ackerson T.Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the early management of acute ischemic stroke: a Guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke2019;50:e344-418

[40] Ahmed N,Turc G.Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018.Eur Stroke J2019;4:307-17 PMCID:PMC6921948

[41] Berge E,Audebert H.European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.Eur Stroke J2021;6:I-LXII PMCID:PMC7995316

[42] Leira EC.EXTEND trial: towards a more inclusive but complex thrombolysis.Stroke2019;50:2637-9

[43] Khatri P,Devlin T.Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial.JAMA2018;320:156-66 PMCID:PMC6583516

[44] Asdaghi N,Coulter JI.Perfusion MR predicts outcome in high-risk transient ischemic attack/minor stroke: a derivation-validation study.Stroke2013;44:2486-92

[45] Parsons M,Bivard A.A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.N Engl J Med2012;366:1099-107

[46] Campbell BC,Churilov L.Tenecteplase versus alteplase before thrombectomy for ischemic stroke.N Engl J Med2018;378:1573-82

[47] Logallo N,Assmus J.Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.Lancet Neurol2017;16:781-8

[48] Ma H,Allport L.Salvage of the PWI/DWI mismatch up to 48 h from stroke onset leads to favorable clinical outcome.Int J Stroke2015;10:565-70

[49] Yang P,Zhang L.DIRECT-MT InvestigatorsEndovascular thrombectomy with or without intravenous alteplase in acute stroke.N Engl J Med2020;382:1981-93

[50] Phan TG,Donnan G,Wood A.Development of a new tool to correlate stroke outcome with infarct topography: a proof-of-concept study.Neuroimage2010;49:127-33